Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Taking the final step from the bench to the hospital or clinic bedside

A new Regenstrief Institute and Indiana University Center for Aging Research (IUCAR) study provides effective strategies to help hospital systems, physicians and other care providers to overcome end zone hurdles and actually take evidence-based research to the patient’s hospital or clinic bedside.

18 May 2010

Taking the final step from the bench to the hospital or clinic bedside

18 May 2010

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

Vect-Horus is a biotechnology company based on the scientific work of Dr. Michel Khrestchatisky and specializes in the development of peptide and pseudo-peptide-based vector molecules for drug targeting and delivery to the central nervous system (CNS).

18 May 2010

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.

18 May 2010

Pfizer, Washington University announce indications discovery collaboration

In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.

18 May 2010

Eisai calls on Alzheimer's patients and caregivers to nominate pharmacists for 2010 C.A.R.E. Pharmacy Award

Eisai Inc., in coordination with the Alzheimer's Association, calls on individuals with Alzheimer's disease and their caregivers across America to nominate local pharmacists for the 2010 C.A.R.E. Pharmacy Award. This award recognizes the vital role that pharmacists play in helping the estimated 5.3 million Americans living with Alzheimer's disease and their almost 11 million caregivers.

18 May 2010

Caffeine normalizes brain function and prevents cognitive decline

Although caffeine is the most widely consumed psychoactive drug worldwide, its potential beneficial effect for maintenance of proper brain functioning has only recently begun to be adequately appreciated. Substantial evidence from epidemiological studies and fundamental research in animal models suggests that caffeine may be protective against the cognitive decline seen in dementia and Alzheimer's disease (AD).

18 May 2010

Altered blood flow leads to falls in elderly people: Research

A new study shows that altered blood flow in the brain due to high blood pressure and other conditions may lead to falls in elderly people. The research will be published in the May 18, 2010, issue of Neurology, the medical journal of the American Academy of Neurology. Each year, unintentional falls in the United States account for more than 16,000 deaths and 1.8 million emergency room visits.

18 May 2010

Cortex first-quarter net income increases to $0.08 per share

Cortex Pharmaceuticals, Inc. reported net income of approximately $5,596,000, or $0.08 per share for the quarter ended March 31, 2010 compared with a net loss of $3,168,000, or $0.07 per share for the corresponding prior year period, with the difference reflecting revenues from the Company's March 2010 transaction with Biovail Laboratories International SRL (Biovail).

17 May 2010

Soliant Health opens up voting for 20 Most Beautiful Hospitals contest

Soliant Health, a leading specialty healthcare staffing provider and part of Adecco Group, has opened up voting for its second annual 20 Most Beautiful Hospitals contest.

15 May 2010

United Spinal Association and ICS co-sponsor first annual conference to empower women with disabilities

United Spinal Association and Independence Care System (ICS), are co-sponsoring the first annual conference to improve the lives, health, and well-being of women with disabilities.

15 May 2010

Power3 Medical Products files provisional patent applications with USPTO

Power3 Medical Products, Inc. announced today that it has filed two provisional patent applications with the United States Patent and Trademark Office (USPTO) - one on Alzheimer's disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer's disease patients.

15 May 2010

Robertson Foundation gifts NYSCF $27 million

The New York Stem Cell Foundation (NYSCF) has received a grant of $27 million from the Robertson Foundation, established by Julian and Josie Robertson.

15 May 2010

Foundation Venture Capital Group makes initial investment of $175,000 to develop test to diagnose AD

As many as 5.3 million Americans, and 35 million people worldwide, are living with Alzheimer's disease, a devastating neurodegenerative illness characterized by memory loss, cognitive decline and widespread destruction of neurons in the brain. Today, there is no definitive diagnosis for the disease, and no treatment to cure it.

15 May 2010

EES launches two surgical staplers to optimize efficiencies and compression during open surgery

Ethicon Endo-Surgery today announced the launch of two new surgical staplers designed to optimize efficiencies and compression during open surgery. The Ethicon Endo-Surgery Linear Cutter 55/75, engineered with novel staple technology and selectable staple heights in one cartridge, provides superior hemostasis for patients and improved efficiencies to surgeons, nurses and facility administrations. The Ethicon Endo-Surgery Intraluminal Stapler, designed with a new tissue compression scale, provides surgeons improved flexibility and control so that they can address the individual needs of each patient.

15 May 2010

Nymox attributes increase in first-quarter net losses to higher clinical trial expenditures

Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009.

14 May 2010

Children with epilepsy say their quality of life is comparable to that of healthy siblings

Children with epilepsy often face multiple challenges - not only seizures but learning, cognitive and school difficulties, side effects from medication, and, not surprisingly, social stigma from their peers.

14 May 2010

Off-label use of AAs among elderly associated with increased risk of diabetes: Study

A new study yields important new evidence that the use of atypical antipsychotics among the elderly for off-label purposes is associated with increased risk of developing diabetes.

14 May 2010

Catheter ablation treatment reduces risks associated with atrial fibrillation

New findings by researchers from the Heart Institute at Intermountain Medical Center in Murray, Utah, reveals treatment of the most common heart rhythm disorder that affects more than two million Americans significantly reduces the risk of stroke, mortality, Alzheimer's disease and other forms of dementia.

14 May 2010

Music enhances new learning of information in AD patients

Researchers from Boston University School of Medicine (BUSM) have shown that patients with Alzheimer's disease (AD) are better able to remember new verbal information when it is provided in the context of music even when compared to healthy, older adults. The findings, which currently appear on-line in Neuropsychologia, offer possible applications in treating and caring for patients with AD.

13 May 2010

Alzheimer's Disease News and Research

Further Reading

Taking the final step from the bench to the hospital or clinic bedside

Taking the final step from the bench to the hospital or clinic bedside

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

Pfizer, Washington University announce indications discovery collaboration

Eisai calls on Alzheimer's patients and caregivers to nominate pharmacists for 2010 C.A.R.E. Pharmacy Award

Caffeine normalizes brain function and prevents cognitive decline

Altered blood flow leads to falls in elderly people: Research

Cortex first-quarter net income increases to $0.08 per share

Soliant Health opens up voting for 20 Most Beautiful Hospitals contest

United Spinal Association and ICS co-sponsor first annual conference to empower women with disabilities

Power3 Medical Products files provisional patent applications with USPTO

Robertson Foundation gifts NYSCF $27 million

Foundation Venture Capital Group makes initial investment of $175,000 to develop test to diagnose AD

EES launches two surgical staplers to optimize efficiencies and compression during open surgery

Nymox attributes increase in first-quarter net losses to higher clinical trial expenditures

Children with epilepsy say their quality of life is comparable to that of healthy siblings

Off-label use of AAs among elderly associated with increased risk of diabetes: Study

Catheter ablation treatment reduces risks associated with atrial fibrillation

Music enhances new learning of information in AD patients

Aneuro: A Year of Neuroscience in Review eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News